Ken Griffin Immunity Bio, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$3.32 - $6.7 $582,660 - $1.18 Million	-175,500 Reduced 52.0%	162,000 $601,000
Q2 2024 Aug 14, 2024	SELL	$4.82 - $9.15 $510,438 - $968,985	-105,900 Reduced 23.88%	337,500 $2.13 Million
Q1 2024 May 15, 2024	BUY	$3.23 - $6.17 $1.12 Million - $2.15 Million	348,000 Added 364.78%	443,400 $2.38 Million
Q4 2023 Feb 14, 2024	SELL	$1.25 - $5.21 $91,375 - $380,851	-73,100 Reduced 43.38%	95,400 $478,000
Q3 2023 Nov 14, 2023	SELL	$1.29 - $3.1 $134,418 - $323,020	-104,200 Reduced 38.21%	168,500 $284,000
Q2 2023 Aug 14, 2023	BUY	$1.53 - $6.41 $9,945 - $41,665	6,500 Added 2.44%	272,700 $758,000
Q1 2023 May 15, 2023	SELL	$1.35 - $4.78 $52,920 - $187,376	-39,200 Reduced 12.84%	266,200 $484,000
Q4 2022 Feb 14, 2023	BUY	$4.35 - $6.77 $430,649 - $670,230	99,000 Added 47.97%	305,400 $1.55 Million
Q3 2022 Nov 14, 2022	BUY	$3.65 - $6.43 $244,915 - $431,453	67,100 Added 48.17%	206,400 $1.03 Million

202

70M

1.68M

1.31M

Ticker IBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 400,304,000
Market Cap $1.8B
Description
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.